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Calcium oxalate stone diseaseMutations in the gene encoding for 4-hydroxy-2-oxoglutarate aldolase (HOGA) are associated with an excessive
production of oxalate in Primary Hyperoxaluria type 3 (PH3). This enzyme is the ﬁnal step of the hydroxyproline
degradation pathwaywithin the mitochondria and catalyzes the cleavage of 4-hydroxy-2-oxoglutarate (HOG) to
pyruvate and glyoxylate. No analyses have been performed to assess the consequences of the mutations identi-
ﬁed, particularly for those variants that produce either full-length or nearly full-length proteins. In this study,
the expression, stability, and activity of nine PH3 human HOGA variants were examined. Using recombinant pro-
tein produced in Escherichia coli as well as transfected Chinese hamster ovary (CHO) cells, it was found that all
nine PH3 variants are quite unstable, have a tendency to aggregate, and retain no measurable activity. A buildup
of HOGwas conﬁrmed in the urine, sera and liver samples fromPH3patients. To determine howHOG is cleaved in
the absence of HOGA activity, the ability of N-acetylneuraminate aldolase (NAL) to cleave HOG was evaluated.
NAL showedminimal activity towards HOG.Whether the expected buildup of HOG inmitochondria could inhibit
glyoxylate reductase (GR), the enzymemutated in PH2, was also evaluated. GR was inhibited by HOG but not by
2-hydroxyglutarate or 2-oxoglutarate. Thus, one hypothetical component of themolecular basis for the excessive
oxalate production in PH3 appears to be the inhibition of GR by HOG, resulting in a phenotype similar to PH2.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Primary hyperoxalurias (PH) are autosomal recessive disorders
characterized by defects in glyoxylate metabolism leading to ex-
cess oxalate production and calcium oxalate stone formation
[1–3]. PH type 1 (PH1) is caused by a functional deﬁciency in the
peroxisomal enzyme, alanine:glyoxylate aminotransferase (AGT),
which normally converts glyoxylate to glycine (Fig. 1). PH type 2
(PH2) is caused by mutations in mitochondrial and cytoplasmic
glyoxylate reductase (GR), which normally reduces glyoxylate to
glycolate. Recently, a third PH classiﬁcation, PH type 3 (PH3,
OMIM ID: 613616), was identiﬁed in individuals with previously
unclassiﬁed forms of PH [4–6]. In PH3, 13 different mutations in
mitochondrial 4-hydroxy-2-oxoglutarate aldolase (HOGA; EC 4.1.
3.16; also known historically as 2-keto-4-hydroxyglutarate aldol-
ase and 4-hydroxy-2-ketoglutarate aldolase) have been identiﬁed.ndDepartment of Biochemistry,
Winston-Salem, NC 27157, USA.
ther).
ew Trails Drive, TheWoodlands,
l rights reserved.This enzyme functions in the ﬁnal step of the 4-hydroxyproline
(Hyp) catabolic pathway leading to the production of pyruvate
and glyoxylate from 4-hydroxy-2-oxoglutarate (HOG) [7–9].
It has been hypothesized that the PH3 mutations may activate or
deactivate HOGA [4,5,10]. Mutations leading to HOGA activation
would cause increased glyoxylate production and could result in
the observed PH3 phenotype. An increase in glyoxylate production
could only occur if this activation was coupled with an increased
turnover of Hyp, which could potentially be induced by an increase
in collagen turnover. A more conventional hypothesis is that these
mutations cause HOGA to be inactivated, either by alterations in
the active site, oligomeric structure, premature degradation, or
mistargeting to the wrong subcellular compartment. The latter is
the case with some PH1 mutations that lead to the mistargeting of
AGT to the mitochondria [11]. A recent report of a patient with
two nonsense mutations early in the protein sequence at residues
39 and 70, supports a scenario where HOGA is inactive [6]. However,
the majority of the remaining HOGA variants produce a full-length
protein that could have activity. An assessment of the activity and
targeting of these variants has not yet been performed. Given that
a loss in HOGA activity and a reduction in glyoxylate levels would
in theory beneﬁt all PH patients, how HOGA inactivation could
lead to a PH phenotype is a conundrum.
Fig. 1. Metabolism of 4-hydroxyproline and glyoxylate. Four mitochondrial enzymes are responsible for 4-hydroxproline (Hyp) breakdown: hydroxyproline oxidase (HPOX),
Δ1-pyrroline-5-carboxylate dehydrogenase (1P5CDH), aspartate aminotransferase (AspAT), and 4-hydroxy-2-oxoglutarate aldolase (HOGA). The terminal HOGA reaction cleaves
4-hydroxy-2-oxoglutarate (HOG) into pyruvate and glyoxylate. A variety of enzymes, including alanine-glyoxylate aminotransferase (AGT), D-amino acid oxidase (DAO), glyoxylate
reductase (GR), and lactate dehydrogenase (LDH), can act on glyoxylate produced from 4-hydroxy-2-oxoglutarate cleavage. AGT, GR, and HOGA are mutated within primary
hyperoxaluria patients (types 1, 2, and 3, respectively).
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human HOGA (hHOGA), alone and in complex with one of its products,
pyruvate [10]. Using this structural information, the PH3 mutations can
be organized into two groups (Fig. 2). The ﬁrst group consists of muta-
tions that presumably disrupt the active site architecture (R70P, R97C,
P190L, T280I, G287V, R303C). The second group ofmutations ismore dis-
tant from the active site and includes C257G, a truncation of 71 residues
from the C-terminus (R255X), and ΔE315 where one Glu within a Glu
triplet repeat is lost. It is hypothesized that this second groupofmutations
affects the overall folding and tetrameric oligomeric state of hHOGA [10].Fig. 2. Location of PH3 hHOGAmutations. (A) Viewof hHOGA tetramer illustrating Arg255, Cys2
Zoom region illustrating Thr280, Gly287, and Arg303. Atom colors are as follows: blue, nitroge
portion of the protein structure leading fromG76-x-x-G-E80 to Glu88 is shown in light blue. HO
model with green carbon atoms. Hydrogen bonds are shown using dashed yellow lines. (C) Zo
sphere. The portion of the protein structure leading from Pro190 to Lys196 is colored in yellow
1.3, Schrödinger, LLC.) using the pyruvate-Schiff base complex structure (PDB ID: 3S5O).Theworkpresentedherein describes the stability andactivity analyses
of nine different PH3mutations in hHOGA using recombinant expression
in Escherichia coli and expression in transfected Chinese hamster ovary
(CHO) cells. Additionally, the level of HOG in the urine, sera and liver sam-
ples from PH3 patients was evaluated. The fate of HOG was assessed in
two ways. The cytosolic protein, N-acetylneuraminate aldolase (NAL),
which has signiﬁcant homology with HOGA and the potential to cleave
HOG, [5] was tested for its ability produce glyoxylate from HOG. Given
the chemical similarity of HOG to the substrates of other glyoxylate
metabolizing enzymes, the ability of HOG to inhibit GR was tested.57 (cyan), and Asp315 (yellow). The truncation caused by R255X is illustrated in gray. (B)
n; orange, carbon; red, oxygen. The G76-x-x-G-E80 motif is illustrated as a blue tube. The
G is shown in its R-form bound to Lys196 as a stick rendering surrounded by a spaceﬁlling
om region illustrating Arg70, Arg97, and Pro190. A potassium atom is shown as a purple
. This ﬁgure was generated with PyMOL (The PyMOLMolecular Graphics System, Version
1546 T.J. Riedel et al. / Biochimica et Biophysica Acta 1822 (2012) 1544–1552Altogether, this study supports the novel hypothesis that the inhibition of
GR by HOG is a key part of the molecular basis for PH3.
2. Material and methods
2.1. Recombinant expression and puriﬁcation of human HOGA variants
The human HOGA gene (HOGA1) was subcloned into the pMal ex-
pression vector (New England BioLabs) so that the mitochondrial
targeting sequence was removed (i.e., the protein started at residue
26), in order to produce the mature form of the protein. In this pro-
cess, an intervening PreScission protease (GE Healthcare) cleavage
sequence was engineered to facilitate the removal of maltose binding
protein (MBP). The R70P, R97C, P190L, R255X, C257G, T280I, G287V,
R303C, and ΔE315 hHOGA variants were made using the QuikChange
site-directed mutagenesis procedure (Stratagene).
Thewild-type (WT) andmutant hHOGA variantswere overexpressed
in 6 L cultures of BL21-Gold (DE3) E. coli at 37 °C. The culturewas induced
at 16 °C overnight by the addition of 0.3 mM isopropyl-β-D-thio-
galactoside (IPTG), once the OD600 reached 0.5–0.7. The cells were
resuspended in 20 mM TRIS pH 8.0, 200 mM NaCl and lysed using an
Avestin Emulsiﬂex-C5 cell homogenizer. The cleared cell lysate was ﬁrst
passed over an amylose column (New England Biolabs) pre-equilibrated
with 20 mM TRIS pH 8.0, 200 mM NaCl. Bound MBP-hHOGA was eluted
off the column via the addition of 10 mMmaltose. The desired fractions,
as determined by SDS-PAGE analysis, were pooled, dialyzed against
20 mM TRIS pH 8.5, and fractionated on a Q-Sepharose HP column (GE
Healthcare) with a 0–0.5 M NaCl gradient over 300 mL. Overnight dialy-
sis at 4 °Cwith PreScission Protease (50:1) and 5 mMDTT allowed for the
cleavage of MBP from HOGA. Glutathione S-Sepharose was used to re-
move the PreScission protease. The fractions containing HOGA were fur-
ther puriﬁed via passage over a Superdex 200 size-exclusion column
equilibrated with 20 mM HEPES pH 7.5, 100 mM NaCl. The protein was
concentrated to 1–10 mg mL−1, aliquoted, frozen with liquid N2, and
stored at −80 °C. Typical yields were 30 mg for WT hHOGA and 0.5–
1 mg for the PH3 variants of hHOGA per 6 L culture.
2.2. Measurement of recombinant hHOGA activity
A standard lactate dehydrogenase (LDH) coupled-enzyme assay
was used to assess the activity of hHOGA by monitoring the produc-
tion of pyruvate from the cleavage of HOG, which was synthesized
as previously described [10]. The 200 μL reactions contained 75 or
1500 nM hHOGA, 200 μM NADH, 100 mM TRIS pH 8.5, 200 mU LDH
(Sigma; Rabbit muscle Type 2), and 400 μM HOG. The reaction time
course was collected for 5 min for WT HOGA. The reactions for the
PH3 variants were allowed to proceed for up to 10 h at 37 °C before
the addition of NADH and LDH and subsequent measurement at
340 nm using a Cary50 spectrophotometer. The reactions were run
in triplicate and repeated on several different days with fresh aliquots
of hHOGA and HOG. Reaction rates were converted to μM min−1
using the extinction coefﬁcient for NADH (ε=6220 M−1 cm−1).
The kcat, KM, and kcat/KM values for HOG were determined utilizing
nonlinear regression analysis in the enzyme kinetics module of
SigmaPlot 11.0 (Systat Software, San Jose, CA).
2.3. Size exclusion chromatography and dynamic light scattering analysis
of hHOGA variants
Analytical size-exclusion chromatography (SEC) on aWaters analyt-
ical HPLC system was performed using a TSK-gel G4000SWXL column
(Tosoh Bioscience) equilibrated at room temperature with 20 mM
HEPES pH 7.5, 100 mM NaCl. The calibrants used were blue dextran
(2000 kDa), thyroglobulin (660 kDa), catalase (232 kDa), aldolase
(158 kDa), ovalbumin (43 kDa), and ribonuclease A (12.7 kDa) (GE
Healthcare). Fifty microliters of each sample at 0.5 mg mL−1 wasinjected using an autosampler and eluted from the column at a ﬂow
rate of 0.5 mL min−1. Additionally, dynamic light scattering data were
collected on 0.5 mg mL−1 hHOGA solutions, in the same buffer as
above, using a Malvern Zetasizer NanoS instrument.2.4. Cell culture and transfection
Chinese hamster ovary (CHO) cells were routinely grown at 37 °C in
F-12K media (Gibco, NY, USA) supplemented with 10% fetal bovine
serum (FBS) (Thermo Fisher HyClone, Logan, UT) in a humidiﬁed atmo-
sphere containing 5% CO2, and were used only until passage 20. CHO
cells were seeded in 24-well plates at a density of 1×105cells/well
24 h before DNA transfection. Transfection with full length HOGA DNA
constructs (pcDNA 3.1, Invitrogen), containing a C-terminal V5-tag,
was performed using Mirus TransIT CHO reagents (Mirus Bio LLC,
Madison, WI) according to the recommendations of the manufacturer.
Following the 24 h transfection, cells were washed three times with
PBS and lysed in a cell lysis buffer containing 25 mM HEPES buffer, pH
7.1, 0.1% Triton-X and Halt protease inhibitor cocktail (Pierce, Rockford,
IL). The cell lysate was used immediately for HOGA activity assays and
Western blot analyses. The protein content of CHO cell lysateswasmea-
sured using a Coomassie Plus assay kit (Pierce, Rockford, IL), with bo-
vine serum albumin as the standard, after dissolution of the cellular
material with 0.1 M NaOH.2.5. Immunostaining
CHOcellswere transfected as described above in Lab-Tek II four cham-
ber slides (Nalge Nunc International, Rochester, NY) at 1×105cells/
chamber for 24 h. After the 24 h transfection period, cells were washed
with Hank's buffered salt solution (HBSS) (Gibco, NY, USA), ﬁxed for
50 min in 3.7% formaldehyde diluted in HBSS, washed with HBSS, and
permeabilized with 0.1% Triton-X for 20 min. They were then washed
with HBSS, blocked with 5% FBS in HBSS for 20 min, and immuno-
stained with afﬁnity-puriﬁed rabbit antibodies to human recombinant
HOGA (antibodies generated by Lampire Biological Laboratories,
Pipersville, PA), mouse anti-cytochrome C (BD Biosciences, San Jose,
CA), anti-rabbit Alexa Fluor 594 (Invitrogen, Grand Island, NY) and
anti-mouse Alexa Fluor 488 (Invitrogen) for 1 hr at room temperature.2.6. Fluorescence microscopy
Confocal images of transfected CHO cells were obtained with a Zeiss
LSM510 confocal microscope system equipped with a krypton-argon
Omnichrome laser with excitation wavelengths of 488 nm and 598 nm
for ﬂuorescein and rhodamine, respectively (Zeiss, Thornwood, NY).2.7. HOGA enzyme activity by reversed phase high pressure liquid
chromatography
HOGA activity of CHO cell lysates following transfection was
performed by measuring the glyoxylate produced from HOG. Assays
were performed at 37 °C in TRIS, pH 8.5, 0.5 mM HOG containing
typically up to 5% CHO lysate. Enzyme activity was stopped with
0.5 M perchloric acid. Glyoxylate was measured by reversed phase
high pressure liquid chromatography (HPLC) after derivatization
with phenylhydrazine. Samples were incubated in the dark for
15 min with 10 mmol L−1 phenylhydrazine, and phenylhydrazones
formed were immediately measured using a Microsorb 100 Å, 5 μm,
C18, 150 mm×4.6 mm, column (Varian Inc., Lexington, MA) with
100 mM ammonium acetate, pH 6.8, 4.4% acetonitrile, and 4.4%
methanol as the mobile phase at a ﬂow rate 1 mL min−1, room
temperature.
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SDS-PAGE of transfected CHO lysates was performed with a Bio-Rad
Ready Gel System (Bio-Rad Laboratories, Hercules, CA) under reducing
conditions using a 6% stacking gel and a 12% resolving gel. After
SDS-PAGE, the samples were electroblotted onto Hybond-C nitrocellu-
lose membranes (Amersham Biosciences, Piscataway, NJ). Membranes
were incubated for 1 h in 5% (w/v) non-fat dried milk dissolved in
PBS, pH 7.4, containing 1% (v/v) Tween-20, followed by incubation for
1.5 hr at room temperature with rabbit anti-HOGA (1 μg mL−1) and
mouse anti-α Tubulin (0.2 μg mL−1) (Invitrogen Carlsbad, CA). The
membrane was then washed and incubated for 1 hr at room tempera-
ture with peroxidase-conjugated goat anti-rabbit immunoglobulin G
(0.2 μg mL−1) and goat anti-mouse immunoglobin G (0.2 μg mL−1)
(Dako Corporation, Carpinteria, CA). Enhanced chemiluminescence
(Amersham Biosciences) was used to visualize immunoreactive bands.
2.9. Measurement N-acetylneuraminate lyase activity
Recombinant N-acetylneuraminate lyase (NAL) from E. coli K12
and N-acetylneuraminate (Neu5Ac) were purchased from Sigma. A
standard lactate dehydrogenase (LDH) coupled-enzyme assay based
on the work of Joerger et al. was used to assess the activity of NAL
by monitoring the production of pyruvate from the cleavage of
Neu5Ac [12]. The decrease in NADH absorbance at 340 nm was con-
tinuously monitored. Reaction rates were converted to μM min-1
using the extinction coefﬁcient for NADH (ε=6220 M−1 cm−1).
The 200 μL reactions contained 16 nM NAL, 150 μM NADH, 20 mM
TRIS pH 7.5, 200 mU LDH (Sigma; Rabbit muscle Type 2), and 0.25–
32 mM Neu5Ac. NAL activity with HOG as a substrate was also tested
with 40 nM NAL and 0.3-2.4 mM HOG using the above conditions. All
reactions were run at 25 °C in triplicate and repeated on several dif-
ferent days with fresh aliquots of NAL, Neu5Ac, and HOG. The kcat,
KM, and kcat/KM values for Neu5Ac and HOG were determined utiliz-
ing nonlinear regression analysis in the enzyme kinetics module of
SigmaPlot 11.0 (Systat Software, San Jose, CA).
2.10. Recombinant expression and puriﬁcation of human GR
The full length human GR gene (GRHPR) was subcloned into the
pET28b expression vector (Novagen) which contains a thrombin cleav-
able N-terminal His tag. GRwas overexpressed in a 10 L fermentation of
C41 (DE3) E. coli at 37 °C. The culture was induced by the addition of
0.1 mM IPTG overnight, once the OD600 reached 0.7 and the tempera-
ture reached 16 °C. The cells were resuspended in 50 mM HEPES pH
7.9, 500 mM KCl, 0.1% Triton X-100, 10% glycerol, 0.5 mM imidazole,
and lysed using an Avestin Emulsiﬂex-C5 cell homogenizer. The cleared
cell lysate was ﬁrst passed over a nickel nitrilotriacetic acid afﬁnity col-
umn (Qiagen). BoundGRwas elutedwith a 0–250 mM imidazole gradi-
ent. The desired fractions, as determined by SDS-PAGE analysis, were
pooled and dialyzed into 20 mM TRIS pH 8.5, 5 mM dithiothreitol
(DTT), 2 mM EDTA, 10% glycerol and fractionated on a Q-Sepharose
HP column (GE Healthcare) with a 0–0.5 M NaCl gradient over
300 mL. The fractions containing GR were pooled and treated with
0.2 Umg−1 biotinylated thrombin (Novagen) at 4 °C overnight to
cleave the His tag. Treatment with streptavidin agarose (Novagen)
allowed for the removal of thrombin before further puriﬁcation via pas-
sage over a Superdex 200 size-exclusion column equilibrated with
20 mM TRIS pH 8.5, 100 mM NaCl, 2 mMDTT, 5% glycerol. The protein
was concentrated to 10 mg mL−1, aliquoted, frozen on liquid N2, and
stored at−80 °C.
2.11. Measurement of recombinant GR activity and inhibition
GR activity wasmeasured bymonitoring the oxidation of NADPH, the
cofactor of the enzyme, at 340 nm using a Cary50 spectrophotometer.The 200 μL reactions contained 3 nM GR, 200 μM NADPH, 100 mM po-
tassiumphosphate pH7.5, 100 mMKCl, and44–700 μMglyoxylate. Reac-
tion rates were converted to μM min−1 using the extinction coefﬁcient
for NADPH (ε=6220 M−1 cm−1). GR inhibition by HOG was tested by
pre-incubating 3 nM GR with 0–10 mM HOG for 10 min at 37 °C before
adding the glyoxylate. All reactions were run at 37 °C in triplicate and re-
peated on several different dayswith fresh aliquots of GR, glyoxylate, and
HOG. The kcat, KM, and kcat/KM values for glyoxylate and Ki value for HOG
were determined utilizing nonlinear regression analysis in the enzyme
kinetics module of SigmaPlot 11.0 (Systat Software, San Jose, CA).
Additional compounds (glutarate, 2-oxoglutarate, 2-hydroxyglutarate,
oxaloacetate, and oxalate) were tested at 10 mM for GR inhibition
using the above conditions. All compounds were purchased from
Sigma with the exception of 2-hydroxyglutarate (Toronto Research
Chemicals).
2.12. HOG analysis by RFIC-MS
Reagent-free™ ion chromatography coupled with negative
electrospray mass spectrometry (RFIC-MS) (Dionex Corp.) was
used to quantitate HOG in serum, urine and liver. Serum and
urine samples were ﬁltered through Nano-sep centrifugal ﬁlters
(VWR International, Batavia, IL) with a 10,000 nominal molecular
weight limit (NMWL), and the ultra-ﬁltrate diluted in water prior
to RFIC-MS. Frozen liver tissue was extracted with 10% ice cold tri-
chloroacetic acid (TCA). This preparation was vortexed continu-
ously for 1 min at 4 °C, frozen at −80 °C for 10 min to promote
protein precipitation, thawed and vortexed again continuously
for 1 min at 4 °C. Precipitate was removed by centrifugation and
TCA in the supernatant removed by vigorously vortexing with 3
volumes of 1,1,2-trichlorotriﬂuoroethane (FREON)-trioctylamine
(3:1, vol/vol; Aldrich, Milwaukee, WI), centrifugation at 4 °C to
promote phase separation, and collecting the upper aqueous layer
for analysis. The IC portion of the IC-MS consists of a 2×250 mm
AS11-HC anion exchange column with guard, potassium hydroxide
eluent generator, and ASRS300 suppressor. A Thermo-Finnigan
MSQ™ ELMO single quadrupole mass spectrometer was used to de-
termine HOG levels using select-ion monitoring (SIM) at the mass/
charge ratio of 161. The limit of detection of HOG by RFIC-MS is
0.06 μM. The disodium salt of HOG was purchased from Santa
Cruz Biotechnology (Santa Cruz, CA) for this analysis.
3. Results
The recent identiﬁcation of hHOGA mutations as a cause of PH3 has
highlighted the need to understand how defects in hydroxyproline me-
tabolism can lead to calcium oxalate stone formation. In an earlier re-
port, we presented the three-dimensional structure of hHOGA, deﬁned
the active site residues, and analyzed a variety of site-directed mutants
to evaluate the role of these residues in catalysis [10]. A mapping of
the PH3 variants onto this structure gave insight into thepotentially det-
rimental roles thesemutationsmay have on catalysis and the oligomeric
state of the protein (Fig. 2). However, no experimental information is
available for the functional consequences of PH3 hHOGA point muta-
tions, particularly for the majority of the variants that are not prema-
turely truncated. Thus, an in-depth functional analysis is warranted.
3.1. Expression, puriﬁcation and solution properties of recombinant PH3
hHOGA variants
The nine PH3 HOGA variants (R70P, R97C, P190L, R255X, C257G,
T280I, G287V, R303C, ΔE315) that produce full-length or only partially
truncated proteins were expressed recombinantly in E. coli and puriﬁed.
The overall yields for the PH3 variants were reduced>50-fold compared
to previous WT yields [10]. Several strategies to optimize expression
were investigated. The pET151/D-TOPO N-terminal His-tag containing
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soluble protein was expressed utilizing several different E. coli strains
(i.e., C41(DE3), BL21-Gold(DE3), BL21*(DE3), Rosetta(DE3)), the protein
quickly degraded after cell lysis andwas not recoverable. The presence of
pyruvate in the growth media and puriﬁcation buffers was investigated.
While unsuccessful for the PH3 variants, this method has proven suc-
cessful in stabilizing oligomeric state disrupting variants and increasing
overall yields of the related DHDPS family of enzymes [13–15]. Further
attempts to stabilize the protein by the addition of glycerol and/or DTT
to the buffer also proved unsuccessful.
Given that many proteins have been shown to be stabilized by fusion
to the maltose binding protein (MBP), all of the PH3 variants were pro-
duced (Fig. A.1) using the pMal expression system (New England
BioLabs) using BL21-Gold(DE3) cells [16]. This fusion–strain combina-
tion gave the most soluble protein. During the optimization of the
MBP-tag removal and puriﬁcation scheme, it was determined that the
highest yields could be obtained if the MBP-tag was cleaved just prior
to the ﬁnal preparative size-exclusion column. Even with the optimized
protocol, all the PH3 variants eluted signiﬁcantly earlier when compared
to WT hHOGA, suggesting higher order oligomerization or aggregation.
Analytical size exclusion chromatography experiments were
performed on the hHOGA variants to more closely analyze potential
aggregation (Fig. A.2). All PH3 variants eluted at the void volume sim-
ilar to the Blue Dextran standard (2000 kDa). WT hHOGA eluted at
the same volume as aldolase (158 kDa), consistent with its tetrameric
mass of 131.5 kDa. The PH3 variants were also analyzed by dynamic
light scattering [10]. Compared to WT hHOGA, which gave a single
mono-disperse peak with a diameter of 9.1 nm, all the PH3 variants
exhibited broad peaks of ~100 nm (data not shown). Experiments
attempting to stabilize or rescue the variants via the addition of glyc-
erol, pyruvate, reducing agent (TCEP), NaCl, and various low concen-
trations of urea (2–4 M) all proved unsuccessful and resulted in the
same ~100 nm broad peaks. Altogether, these data support that the
PH3 variants are most likely miss-folded and prone to aggregation
with themselves and potentially other proteins.
3.2. Assessment of subcellular targeting for PH3 hHOGA variants
In an effort to identify whether the PH3 hHOGA mutations were
causing mistargeting within the cell, a phenomenon that occurs with
some variants of AGT within PH1, all PH3 variants were transiently
transfected into Chinese hamster ovary (CHO) cells [11]. These cells
do not contain the HOGA enzyme. Additionally, expression in mamma-
lian cells could help to facilitate correct folding, which was presumably
not fully achieved in the studies of the recombinant proteins. Mito-
chondrial targeting of hHOGA was evaluated by the confocal ﬂuores-
cent imaging of CHO cells (Figs. 3 and A.3) transfected with the
empty pcDNA 3.1 vector, WT hHOGA within the same vector, and the
hHOGA variants. The localization of hHOGA was visualized using a
polyclonal antibody raised against theWT recombinant protein. An an-
tibody for cytochrome C was used as a mitochondrial marker.
CHO cells transfected with WT hHOGA showed coincident ﬂuores-
cence for hHOGA and cytochrome C, indicating that HOGA is targeted
correctly in these cells (Figs. 3 and A.3). In contrast, transfection of the
remaining hHOGA variants, performed at the same time under iden-
tical conditions, resulted in only a few cells per ﬁeld that expressed
HOGA. However, this expression was conﬁned to mitochondria. Im-
portantly, no ﬂuorescence for the PH3 HOGA variants was observed
in the cytoplasm. The Western blot analysis revealed that only the
R70P variant had signiﬁcant protein expression, although ~10 times
lower than WT (Fig. A.4). All of the other PH3 variants showed either
very little protein at the molecular weight for the full-length mono-
mer, other molecular weight bands or no protein at all. Altogether,
these studies support that the PH3 variants of hHOGA are most likely
being degraded. Additional studies are clearly needed to fully under-
stand the impact and mechanism of degradation of the PH3 variants.3.3. Assessment of PH3 mutant activity
It has been proposed that the PH3mutations may either increase or
decrease hHOGA activity [4,5,10]. To discriminate between these pro-
posals, the activity of the PH3 variants was assessed using the recombi-
nant proteins and the cell lysates from the transfection experiments.
The puriﬁed recombinant variants were analyzed using a coupled
assay that relied upon the consumption of NADH and the conversion
of pyruvate to lactate by LDH [10]. Using 75 nM WT hHOGA and
400 μM HOG, a speciﬁc activity of 15.8±2.1 μmol min−1 mg−1 was
obtained. Initial tests with 75 nM of each PH3 variant produced no
measureable rate over background. Additional experiments utilizing
1500 nM of each PH3 variant and 400 μM HOG per reaction over 10 h
also yielded no observable activity over background. Assessment of
HOGA activity using the CHO cell lysates was also performed by directly
monitoring the production of glyoxylate. WT hHOGA activity (74.8±
12.7 pmol min−1 mg−1) was readily detected. However, no activity
could be monitored for the cell lysates from the PH3 variants (data
not shown). Increasing the amount of DNA used for CHO cell transfec-
tion or the amount of cell lysate used in the assay did not result in
measureable activity (data not shown). The limit of detection for the
HPLC-based HOGA activity assay is b4 pmol glyoxylate produced
min−1 mg−1 protein cell lysate. These ﬁndings are consistent with
the low amount of mitochondrially-targeted and full-length hHOGA
PH3 variants within transfected CHO cells and the inactivity observed
for all of the recombinant PH3 hHOGA variants.
3.4. HOG cleavage activity by N-acetylneuraminate lyase
Under normal physiological conditions, HOG is most likely cleaved
solely by HOGA in the mitochondria. The inactivation of HOGA would
result in the buildup of HOG to a non-physiological level. It has been
proposed that HOG could diffuse into the cytosol and be converted to
glyoxylate by a pyruvate aldolase such as N-acetylneuraminate lyase
(NAL; UniProt ID: Q9BXD5) [5]. In an effort to test this hypothesis,
we analyzed E. coli NAL (EcNAL) for HOG cleavage activity. The kinetic
parameters for both the natural substrate, N-acetylneuraminate
(Neu5Ac), and HOG were readily determined using a coupled assay
that relied upon the consumption of NADH and the conversion pyru-
vate to lactate by LDH (Table 1). Comparable kinetic parameters to
other studies were obtained with Neu5Ac as the substrate [12,17].
While EcNAL was able to catalyze the cleavage of HOG, it did so less
effectively with 135- and 161-fold reductions in kcat and kcat/KM,
respectively. These observations suggest that NAL would not be able
to convert a signiﬁcant amount of HOG produced from Hyp to
glyoxylate. Thus, the activity of NAL would not be sufﬁcient to lead
to a PH phenotype.
3.5. GR inhibition by HOG
The inactivation of HOGA would not be expected to lead to the PH
phenotype since glyoxylate would not be produced from Hyp metab-
olism. One possible explanation is that HOG builds up in mitochon-
dria and perhaps the cytoplasm, and inhibits the activity of another
enzyme that could modulate the amount of glyoxylate in the cell.
GR, which is present in the mitochondria and cytosol, is a prime can-
didate. In an effort to better understand the fate of excess HOG in the
cell, we tested the ability of HOG to inhibit human GR. Human GR was
expressed recombinantly in E. coli and puriﬁed. GR activity was mea-
sured by monitoring the oxidation of NADPH, the cofactor of the en-
zyme, during the reduction of glyoxylate to glycolate. In order to
simplify these studies, NADPHwas used at a saturating concentration,
200 μM (KM for NADPH=11 μM) [18]. This analysis yielded apparent
kcat, KM and kcat/KM values of 63 s−1, 253 μM, and 249 mM−1 s−1,
respectively, which are consistent with a previous literature report
[18]. The ability of HOG to inhibit GR was determined by pre-
Fig. 3. Subcellular localization of HOGA variants. Confocal images for CHO cells transfected with HOGA variants. (A) Wild-type hHOGA (clockwise from bottom left): confocal image,
immunoﬂuorescence for HOGA (red), immunoﬂuorescence for cytochrome C (green), merge. (B) Merged images for PH3 variants. See Fig. A.3 for all images for each PH3 mutant.
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the data by non-linear regression analyses showed the best ﬁt to the
partial mixed-type inhibition model (Fig. 4A and B), resulting in a Ki
value of 1.8±0.9 mM for HOG [19]. In this model the lines of the re-
ciprocal plot do not intersect the 1/v y-axis, but do intersect below
and to the left on the 1/[S] x-axis.
Compounds similar to HOGwere also analyzed for GR inhibition at a
concentration of 10 mM: glutarate, 2-oxoglutarate, 2-hydroxyglutarate,
oxaloacetate, and oxalate (Fig. 4C). Glutarate and oxalate had no
observable inhibitory effect. 2-oxoglutarate, 2-hydroxyglutarate, and
oxaloacetate displayed minimal observable inhibition (b6–10% de-
crease in activity). This effect is nominal compared to the 89–91% reduc-
tion observed for 10 mM HOG. Thus, HOG appears to be a speciﬁc
inhibitor of GR. Given the mg–g amounts of Hyp being converted to
HOG via the Hyp catabolic pathway, the HOG produced in PH3 patients
could be at a concentration high enough to inhibit a signiﬁcant propor-
tion, if not all, of the GR within a cell. This inhibition could ultimately
lead to a phenotype similar to PH2 patients, which have inactivating
mutations in GR.
3.6. HOG levels in the urine, liver and sera of PH3 patients
A survey of the gene expression proﬁle for HOGA in a variety of tis-
sues indicated that the highest levels of HOGA were found in the liver,
kidney, pancreas, and small intestine [20]. The inactivity of HOGA in
PH3 patients should lead to a demonstrable increase in the levels of
HOG. Ion chromatography coupled with mass spectroscopy (RFIC/MS)
was used to measure HOG in liver tissue, urine and serum samples
from healthy individuals and patients with PH3, PH2, PH1, and idio-
pathic calcium oxalate kidney stone disease. Urines, tissue and sera
from all patient groups except PH3 patients had HOG levels (Table 2)
below the limit of detection (b0.06 μM). In contrast, all samples fromTable 1
Kinetic parameters for E. coli NAL.
Substrate kcat (min−1) KM (mM) kcat/KM (mM−1 min−1)
Neu5Ac 2.70±0.02 2.4±0.1 1.13±0.020
HOG 0.02±0.003 3.2±0.7 0.007±0.003PH3patients containedHOG. The level of oxalate in a single liver sample
from a PH3patientwas 328 pmol/mg protein, whichwas ~4 fold higher
oxalate thanmeasured in a normal liver sample (83 pmol/mg protein).
These ﬁndings further support that the HOGA variants within PH3 pa-
tients are inactive leading to an increase in HOG within tissues where
Hyp degradation occurs. Additionally, the buildup in HOG can result in
the excessive synthesis of oxalate.
4. Discussion
The catabolism of Hyp, derived from endogenous and dietary sources,
results in the production of glyoxylate, glycolate, glycine, and oxalate
(Fig. 1) within liver and kidney cells [3,21]. The synthesis and breakdown
of these metabolites are altered in PH patients and result in the conver-
sion of more glyoxylate to oxalate, which can lead to the formation of
calcium-oxalate kidney stones, and in extreme cases kidney failure [2].
While the molecular basis for PH1 and PH2 has been well studied, little
is known about PH3 [2,4,5]. Recently, we described the biochemical and
structural characterization of human HOGA, the enzyme mutated in
PH3. The nine PH3 mutations that yield full-length and near full-length
proteins (Fig. 2) can be grouped into twomain classes. The ﬁrst group in-
volves mutations that presumably perturb the active-site architecture.
The second group seems to disrupt the tetrameric structure of hHOGA.
No experimental data to demonstrate the catalytic competence of these
PH3 variants was available.
Our analysis of the recombinant hHOGA PH3 variants, producedwith
optimized expression and puriﬁcation schemes, revealed an inherent in-
stability and tendency to aggregate (Figs. A.1 and A.2). Expression of the
PH3 variants within CHO cells (Figs. 3 and A.3) conﬁrmedmitochondrial
targeting. However, expression of the PH3 variants in these cells resulted
in a signiﬁcant reduction in the amount of protein and in some cases po-
tential degradation products. In contrast toWT hHOGA, the PH3 variants
exhibited no enzymatic activity fromeither expression system. Altogeth-
er, these ﬁndings implicate protein mis-folding, aggregation, and degra-
dation for the loss of the enzymatic activity of hHOGA in PH3 patients.
The exact mechanism, however, remains unknown and will require ad-
ditional cellular and functional studies.
The crystal structure of hHOGA provides a molecular framework
to rationalize how some of the PH3 mutations could lead to inactiv-
ity as a result of miss-folding and aggregation. Three of the PH3
Fig. 4. Kinetic analysis of HOG inhibition of human glyoxylate reductase. (A) v versus
[S] plot. (B) 1/v versus 1/[S] reciprocal plot. The kinetic parameters were determined
through non-linear regression and ﬁtted to the mixed partial inhibition model. ●, no
HOG; ○, 0.31 mM HOG; ▼, 1.25 mM HOG. Parameters calculated from the global ﬁt
of all data: R2=0.988; Ki for HOG, 1.75±0.85 mM; KM for glyoxylate, 267±19 μM;
kcat, 72.7±0.01 s−1. (C) Evaluation of congeners of HOG as inhibitors of GR. Error
bars for all panels are indicated by vertical brackets.
Table 2
Levels of HOG in samples from various patient groups.
















n=6 PH3, 10 PH1, 6 PH2, 10 CaOx SF, and 10 normal urines. n=5 PH3 and 3 normal
sera. n=3 PH3, 6 PH1, and 6 normal livers.
a Data expressed as mean±SD (range).
b CaOx SF, calcium oxalate kidney stone formers.
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active site, but present at the dimer–dimer interface of the tetramer.
A disruption of this interface and the monomer–monomer interface
in the dihydrodipicolinate synthase (DHDPS) enzyme from E. coli, a
homolog of hHOGA, results in a signiﬁcant loss in activity and the re-
quirement for specialized puriﬁcation and stabilization buffers [15,22].
The R255X PH3 variant is a nonsense mutation that would truncatethe entire C-terminal, three-helical bundle (Fig. 2A, gray), also shown
to be a key feature necessary for tetramerization [23]. The C257G vari-
ant is located nearby and may also affect the structural transition be-
tween the TIM barrel and the three-helical bundle (Fig. 2A, cyan). The
ΔE315 variant results in the deletion of one Glu residue in a triplet
Glu motif present in the C-terminal helix (Fig. 2A, yellow). This muta-
tion could potentially alter the entire structure of this helix, also
resulting in the disruption of the tetramer.
At this time it is unclear why the remaining PH3 variants (R70P,
R97C, P190L, T280I, G287V, R303C)would be destabilized, perhaps lead-
ing to their premature degradation. These residues are proximal to the
active site (Fig. 2) and the conserved G76-x-x-G-E80 pyruvate-binding
motif. Based on our previous analysis of a panel of active site mutants,
one would expect moderate losses in activity based on the postulated
roles for each of the active site residues for catalysis and substrate recog-
nition [10]. However, it is possible that these mutations lead to disrup-
tions in the tertiary structure at the core of the protein, which in turn
causes a loss in quaternary structure. For example, Arg303 participates
in a bifurcated salt bridge interaction with Glu88 which is present at
the end of the α-helix following the G76-x-x-G-E80 motif (Fig. 2B,
light-blue). This interaction is also conserved throughout HOGA and
DHDPS enzymes and mutation of Arg303 to Lys would likely cause a
disruption. Additionally, Pro190 is present at the turn just prior to the
essential catalytic residue Lys196 and substrate-positioning residue
Ser198 (Fig. 2C, yellow).Mutation to Leuwould likely disrupt this essen-
tial turn leading to a loss in proper substrate positioning and catalysis. It
is tempting to speculate that the addition of small molecule agents may
help to stabilize these variants and to rescue any residual activity that
could be beneﬁcial to a PH3 patient. Such approaches have been
shown to have some success for some AGT variants of PH1 [24,25].
During the preparation of this manuscript, three additional PH3
mutations were identiﬁed: A36V, Y39X, and R70X [6]. While it is pos-
sible that the A36V variant may retain activity, the Y39X and R70X
truncations would result in short peptides that do not contain the
HOGA catalytic residues which are present after the truncations [10].
The demonstrated inactivity for all HOGA PH3 variants analyzed
lends itself to an important question. With HOG not being converted
to glyoxylate, how do these mutations ultimately result in a PH pheno-
type? One proposal is that the inactivation of hHOGA would lead to a
build-up of HOG inmitochondria and the cytoplasm. At high concentra-
tions, HOG could be converted to glyoxylate by another aldolase such as
NAL [5]. NAL is a cytoplasmic enzyme that catalyzes the cleavage
Neu5Ac to produce pyruvate andN-acetyl-D-mannosamine, a strikingly
similar reaction to that of HOGA. Both the enzymes belong to the NAL
subfamily of (β/α)8-barrel enzymes and the human forms share a
sequence identity of 26.9%. Two of the essential catalytic residues in
hHOGA (Lys196 and Tyr168) are conserved between the two enzymes.
However, differences in the G76-x-x-G-E80 pyruvate bindingmotif exist.
Ser77 in hHOGA is present as a Thr residue in humanNAL.We have pre-
viously shown that the S77T variant of hHOGA exhibited a 7.7-fold re-
duction in kcat [10]. This observation suggests that the human NAL
should be less efﬁcient in the turnover of HOG.
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NAL could potentially perform the HOG cleavage reaction (Table 1). It
should be noted, however, that the rate for the conversion of HOG to
glyoxylate is much slower when compared to the rate for NAL with its
natural substrate, or hHOGA with HOG. One important additional point
to consider is that even if NAL or another enzyme was able to cleave all
of theHOGproduced fromHyp to glyoxylate, this scenario should not re-
sult in a PH phenotype. The end result would be the same amount of
glyoxylate produced from Hyp, which should be readily converted to
glycolate and glycine by the wild-type GR and AGT present in PH3 pa-
tients, respectively. Only if there was a net increase in the ﬂux of metab-
olites through the Hyp pathway would there be a chance for NAL to
produce an increased amount of glyoxylate that could be converted to
oxalate. Thus, we feel that this scenario is most likely not the molecular
basis for PH3.
We propose an alternative hypothesis for the molecular basis for
PH3. Given the chemical similarities between HOG and glyoxylate,
the buildup of HOG within the liver and kidney cells could inhibit
other glyoxylate metabolizing enzymes. Because GR is present in
both the mitochondria and cytoplasm, it seems to be the most logical
candidate. HOG acts as an inhibitor of human GR (Fig. 4) with a Ki
value of ~1 mM. The potency of HOG could be greater, since the
only available form of HOG is a racemic mixture. Given the complex-
ity of the partial mixed inhibition pattern, the mechanistic details of
the inhibition will require additional characterization. Nonetheless,
one possible mechanism for GR inhibition could be that HOG is bind-
ing in part to glyoxylate and the NADPH binding sites. As previously
described, NADPH binds at the interface of the coenzyme binding
and substrate binding domains of GR [26]. Upon NADPH binding,
these domains are thought to rotate up to 18° to complete the sub-
strate binding site. If HOG blocks this action, GR activity would de-
crease. In fact, some of the PH2 causing mutations are thought to
cause a loss in NADPH binding [26]. HOG may also bind to an un-
known remote site, which will require additional kinetic and struc-
tural work to validate.
Since Hyp metabolism is one of the main contributors to glyoxylate
and oxalate levels, a signiﬁcant portion of HOG is mostly likely also
being cleaved to glyoxylate by another enzymeor enzymes,whose iden-
tity and compartmentalization are yet to be determined. The inhibition
of GR by HOG and the presence of LDH in the mitochondria (Fig. 1)
also raise the possibility that this elevated glyoxylate pool is readily
converted to oxalate [27,28]. It is unclear at this timewhether sufﬁcient
HOGmoves into the cytosol to inhibit GRwithin this compartment. This
latter scenario would not be unreasonable and would also lead to an in-
creased conversion of glyoxylate to oxalate. Experiments to investigate
and clarify these concepts are clearly warranted and are in progress uti-
lizing the HOGA knock out mouse.
Given the concentration of HOG required for GR inhibition (~1 mM)
and the putative physiological concentration of HOG (~10 μM based on
the KM value for hHOGA for HOG), one would not expect HOG to inhibit
GR under normal physiological conditions. The loss of HOGA function in
PH3, however, would lead to an increase of HOG. The elevated level of
HOG would be able to inhibit mitochondrial GR. The signiﬁcant increase
in the concentration of HOG in urine, sera and liver samples from PH3 pa-
tients (Table 2) supports this notion. Moreover, Monico et al. reported
that one PH3 patient, a compound heterozygote (R255X mutation and a
splice site variant, IVS700+5G>T insertion), had increased urine oxalate
and L-glycerate levels compared to normal subjects [5]. This observation
would correlate with a PH2-like urinary proﬁle where oxalate and
glycerate levels rise due to the inactivation of GR [11]. Most PH3 patients,
however, exhibit normal glycolate and L-glycerate levels, although these
values are quite variable and sometimes are elevated due to the young
age of the patients (b6 years). The normal L-glycerate in PH3 individuals
would be consistent with the production of hydroxypyruvate in the per-
oxisome (serine:pyruvate aminotransferase activity of AGT) and the cyto-
plasmic hydroxypyruvate reductase activity of GR not being severelyimpacted by a buildup of HOG, whichwill primarily occur only in themi-
tochondrion. The normal glycolate excretion in these patients may also
stem from the possibility that the production of glycolate from glyoxal
in the glyoxylase pathway is the dominant route for glycolate synthesis
in the body [29]. Studies utilizing 13C-Hyp infusions as a metabolic tracer
in normal subjects and PH1-3 patients are in progress to investigate these
intriguing possibilities and questions.
4.1. Conclusions
This study provides theﬁrst functional analysis of the PH3HOGAmu-
tations, within the context of the full-length protein and one relatively
short truncation. The PH3HOGAvariantswere all enzymatically inactive,
presumably due to improper folding leading to aggregation and cellular
degradation. The activity of a related aldolase, NAL, does not appear to
have signiﬁcant HOGA activity. Importantly, HOG is able to inhibit GR.
Given the mg–g amounts of Hyp being degraded from endogenous and
dietary sources of collagen on a daily basis, the levels of HOG could rise
substantially, as supported by the detection of HOG in the urine, liver,
and serum of PH3 patients. Thus, the inactivation of HOGA ultimately re-
sults in a PH2-like phenotype characterized by GR inhibition, glyoxylate
buildup, and oxalate formation. Additional cellular and animal studies
are in progress to investigate this intriguing hypothesis. The ﬁndings
presented herein also support that the pharmacological and/or dietary
modulation of the Hyp degradation pathway could have a signiﬁcant im-
pact on PH3 patients by decreasing HOG levels. Furthermore, inhibition
of Hyp metabolism may prove to be useful for all PH patients, as any re-
duction in glyoxylate formation could be beneﬁcial.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2012.06.014.
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